{"id":"intra-nasal-dexmedetomidine","safety":{"commonSideEffects":[{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexmedetomidine binds to alpha-2 adrenergic receptors in the locus coeruleus and other brain regions, reducing norepinephrine release and producing dose-dependent sedation and analgesia. The intranasal formulation allows non-invasive delivery for rapid onset of action. This mechanism provides sedation without respiratory depression, making it suitable for procedural sedation and anxiety management.","oneSentence":"Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating alpha-2 receptors in the central nervous system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:49:31.760Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Procedural sedation and anxiolysis via intranasal administration"},{"name":"Pediatric preoperative anxiety"}]},"trialDetails":[{"nctId":"NCT06867289","phase":"NA","title":"Study of the Efficacy of Moderate Sedation With Intra-NAsal Dexmedetomidine Monitored by EEG MOnitoring","status":"RECRUITING","sponsor":"Centre Hospitalier Régional Metz-Thionville","startDate":"2025-04-08","conditions":"Procedural Sedation and Analgesia, Pediatric ALL","enrollment":50},{"nctId":"NCT04669457","phase":"PHASE4","title":"Pediatric Delirium","status":"ENROLLING_BY_INVITATION","sponsor":"University of Massachusetts, Worcester","startDate":"2021-04-27","conditions":"Pediatric Delirium","enrollment":60},{"nctId":"NCT06466915","phase":"PHASE4","title":"Propofol vs. Nasal Dexmedetomidine in Pediatric Agitation and Delirium","status":"COMPLETED","sponsor":"Baskent University Ankara Hospital","startDate":"2023-06-01","conditions":"Comparison of the Effects of Propofol and Nasal Dexmedetomidine","enrollment":162},{"nctId":"NCT06741566","phase":"EARLY_PHASE1","title":"Pre-operative Intra-nasal Dexmedetomidine or Insulin for Prevention of Early Post-operative Cognitive Dysfunction in Patients Undergoing Elective Coronary Artery Bypass Graft.","status":"NOT_YET_RECRUITING","sponsor":"Minia University","startDate":"2024-12-27","conditions":"Post Operative Cognitive Dysfunction","enrollment":150},{"nctId":"NCT03069638","phase":"PHASE4","title":"Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2017-02-01","conditions":"Juvenile Idiopathic Arthritis, Joint Inflammation","enrollment":68},{"nctId":"NCT03668951","phase":"PHASE1","title":"Pharmacokinetic Study of Dexmedetomidine After Intra-Nasal and Buccal Dosing in Children","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-08-20","conditions":"Heart Diseases","enrollment":18},{"nctId":"NCT03806777","phase":"PHASE4","title":"Intra-nasal Dexmedetomidine for Children Undergoing MRI Imaging","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2019-02","conditions":"MRI Sedation","enrollment":180},{"nctId":"NCT02836431","phase":"PHASE1","title":"Pharmacokinetic Study of Dexmedetomidine After Intra-nasal Dosing in Children","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2016-01","conditions":"Heart Disease","enrollment":18},{"nctId":"NCT02776189","phase":"PHASE4","title":"Dexmedetomidine Verses Propofol for Paediatric MRI Brain","status":"COMPLETED","sponsor":"Maharashtra University of Health Sciences","startDate":"2012-10","conditions":"Brain Diseases","enrollment":70},{"nctId":"NCT00654329","phase":"PHASE4","title":"Dexmedetomidine vs Fentanyl for BMT","status":"COMPLETED","sponsor":"Children's National Research Institute","startDate":"2005-08","conditions":"Otitis","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Precedex"],"phase":"marketed","status":"active","brandName":"Intra-nasal Dexmedetomidine","genericName":"Intra-nasal Dexmedetomidine","companyName":"University of Massachusetts, Worcester","companyId":"university-of-massachusetts-worcester","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexmedetomidine is a selective alpha-2 adrenergic agonist that produces sedation, analgesia, and anxiolysis by activating alpha-2 receptors in the central nervous system. Used for Procedural sedation and anxiolysis via intranasal administration, Pediatric preoperative anxiety.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}